Identify Prognostic Biomarkers of Lung Cancer

• Conditions: Lung Cancer; Lung Adenocarcinoma; Lung Squamous Cell Carcinoma; Non Small Cell Lung Cancer

• Registration Number: NCT05010330
• Lead Sponsor: RenJi Hospital

Brief Summary

Multi-omics and Clinical Data Analysis is potential to predict the prognosis of lung cancer patients.

Detailed Description

Lung cancer is the leading cause of cancer-related death in China. In order to improve prognosis of lung cancer as well as provide new therapeutic targets, the identification of effective biomarkers for the prognosis of lung cancer is of great significance. It has been reported that some small molecules such as lncRNA, circRNA and polypeptides in human plasm have good prospects in diagnosing or evaluating the stage of diseases. In this study, we planned to use multi-omics combined with clinical data to discovery some small molecules that are potential to predict the prognosis of lung cancer patients. In addition, we want to construct a new risk score model that provide a candidate model for prognostic evaluation of lung cancer. And we hope our study can provide insights for precision immunotherapy of lung cancer by exploring the differences in clinical characteristics, tumor mutation burden, and tumor immune cell infiltration between different risk score groups.

Study Timeline

• Study Start: 2020-07-01
• Study First Submitted: 2021-07-27
• Status Verified: 2021-08
• Study First Submitted QC: 2021-08-14
• Last Update Submitted: 2021-08-14
• Study First Posted: 2021-08-18
• Last Update Posted: 2021-08-18
• Primary Completion: 2021-09-20
• Study Completion: 2021-09-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

• Patients diagnosed with lung cancer;
• Untreated lung cancer patients;
• No history of chronic or serious diseases, such as cardiovascular disease, liver disease, kidney disease, respiratory disease, blood disease, lymphatic disease, endocrine disease, immune disease, mental disease, neuromuscular disease, gastrointestinal system disease, etc.

Exclusion Criteria

• Patients with other tumors;
• Lung cancer patients who had been treated;
• Abnormal liver and kidney function;
• Acute and chronic infectious diseases

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Identify some prognostic biomarkers in lung cancer.	1 week	1. Our study will identify some biomarkers that can predict the prognosis of lung cancer patients.; 2. Our study will construct a new risk score model that provide a candidate model for prognostic evaluation of lung cancer.; 3. Our research will provide insights for precision immunotherapy of lung cancer by exploring the differences in clinical characteristics, tumor mutation burden, and tumor immune cell infiltration between different risk score groups.

Trial Locations

Locations (1)

Renji Hospital, Shanghai Jiaotong University school of medicine; 🇨🇳 Shanghai, China